Double bare metal stent deployment combined with intraductal radiofrequency ablation for malignant distal biliary obstruction: a prospective pilot study

• Published in: Scientific reports Vol. 13; no. 1; p. 2654
• Main Authors: Inoue, Tadahisa, Ibusuki, Mayu, Kitano, Rena, Sakamoto, Kazumasa, Kimoto, Satoshi, Kobayashi, Yuji, Sumida, Yoshio, Nakade, Yukiomi, Ito, Kiyoaki, Yoneda, Masashi
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 14.02.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 692/4020; 692/700/565; Ablation; Cholestasis - etiology; Cholestasis - surgery; Humanities and Social Sciences; Humans; Implants; multidisciplinary; Occlusion; Patients; Pilot Projects; Prospective Studies; Radiofrequency ablation; Radiofrequency Ablation - adverse effects; Retrospective Studies; Science; Science (multidisciplinary); Sludge; Stents; Stents - adverse effects; Success; Treatment Outcome
• DOI: 10.1038/s41598-023-29955-5
• ISSN: 2045-2322

Although uncovered self-expandable metal stents (SEMSs) possess certain advantages such as averting cystic duct obstruction and stent migration, they are susceptible to ingrowth occlusion. The combination of the double bare stent (DBS) and endobiliary radiofrequency ablation (RFA) may reduce ingrowth. Hence, this study aimed to examine the utility of this method for the treatment of unresectable malignant distal biliary obstruction (MDBO). This prospective, single-center, pilot study enrolled 51 patients who met the eligibility criteria between February 2020 and January 2022. The study outcomes included technical success, clinical success, recurrent biliary obstruction (RBO), and other adverse events (AE) besides RBO associated with DBS placement with RFA for MDBO. The technical success rate was 98.0% (50/51). Clinical success was achieved in all patients in whom technical success was achieved. The rates of early and late AEs were 5.9% (3/51) and 8.0% (4/50), respectively. The incidence rate of RBO was 38.0% (19/50). Sludge occlusion, ingrowth occlusion, and overgrowth occlusion occurred in 26.0% (13/50), 8.0% (4/50), and 2.0% (1/50) of patients, respectively (the main cause of RBO was undeterminable in 1 patient). The median time to RBO was 241 days. DBS with RFA showed good technical feasibility, good long-term outcomes, acceptable AE rates, and most importantly, a low ingrowth occlusion rate when employed for the treatment of MDBO.